A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
מצבים רפואיים
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder · Major Depressive Disorder · Tardive Dyskinesia
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Neurocrine Clinical Site, Bryant, Arkansas, United States
Neurocrine Clinical Site, Chino, California, United States
Neurocrine Clinical Site, Fountain Valley, California, United States
Neurocrine Clinical Site, Fresno, California, United States
Neurocrine Clinical Site, Long Beach, California, United States
Neurocrine Clinical Site, Orange, California, United States
Neurocrine Clinical Site, Redlands, California, United States
Neurocrine Clinical Site, San Diego, California, United States
Neurocrine Clinical Site, Bonita Springs, Florida, United States
Neurocrine Clinical Site, Hialeah, Florida, United States
Neurocrine Clinical Site, Miami, Florida, United States
Neurocrine Clinical Site, Miami, Florida, United States
Neurocrine Clinical Site, Orange City, Florida, United States
Neurocrine Clinical Site, Port Charlotte, Florida, United States
Neurocrine Clinical Site, Tampa, Florida, United States
Neurocrine Clinical Site, Augusta, Georgia, United States
Neurocrine Clinical Site, Marietta, Georgia, United States
Neurocrine Clinical Site, Naperville, Illinois, United States
Neurocrine Clinical Site, Omaha, Nebraska, United States
Neurocrine Clinical Site, Independence, Ohio, United States
Neurocrine Clinical Site, Austin, Texas, United States
Neurocrine Clinical Site, Richmond, Virginia, United States
מובילי המחקר
Clinical Development Lead
Study Director
Neurocrine Biosciences